Trial
NCT04093323
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Roswell Park Cancer Institute
Collaborators
National Cancer Institute (NCI)
Condition
HLA-A2 Positive Cells Present
Intervention
Alpha-type-1 Polarized Dendritic Cells
Why stopped
Funding completed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-25